Skip to main content
International Journal of Bipolar Disorders
Figure 2 | International Journal of Bipolar Disorders

Figure 2

From: Who will benefit from antidepressants in the acute treatment of bipolar depression? A reanalysis of the STEP-BD study by Sachs et al. 2007, using Q-learning

Figure 2

RAD design. At the beginning (stage 1), there are 365 patients in total. Eighty-five patients take Bupropion, 93 patients take Paroxetine, and 187 patients take placebo. After 6 weeks, 104 patients’ information are lost. Only 78 patients are tracked with non-response at the end of stage 1. At stage 2, patients with non-response are assigned to secondary treatment intervention. Patients taking Bupropion or Paroxetine at stage 1 will increase current doses. But patients taking placebo at stage 1 will be assigned Bupropion or Paroxetine.

Back to article page